

CITATION REPORT

List of articles citing

Potential Cost-Savings From the Use of the Biosimilars in Slovakia

DOI: 10.3389/fpubh.2020.00431
Frontiers in Public Health, 2020, 8, 431.

Source: <https://exaly.com/paper-pdf/76147650/citation-report.pdf>

Version: 2024-04-25

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
5	Current status of biosimilars in Turkey: A survey among medical oncologists. <i>Journal of Oncology Pharmacy Practice</i> , 2021 , 10781552211031643	1.7	1
4	Evidence-based public policy making for medicines across countries: findings and implications for the future. <i>Journal of Comparative Effectiveness Research</i> , 2021 , 10, 1019-1052	2.1	7
3	Validation of GWAS-Identified Variants for Anti-TNF Drug Response in Rheumatoid Arthritis: A Meta-Analysis of Two Large Cohorts. <i>Frontiers in Immunology</i> , 2021 , 12, 672255	8.4	1
2	Rapid monitoring of health services use following a policy to switch patients from originator to biosimilar etanercept-a cohort study in British Columbia.. <i>BMC Rheumatology</i> , 2022 , 6, 5	2.9	1
1	The Impact of Reimbursement Practices on the Pharmaceutical Market for Off-Patent Medicines in Slovakia.. <i>Frontiers in Pharmacology</i> , 2021 , 12, 795002	5.6	0